Abstract
Thyroid hormone is a pleiotropic hormone with widespread biological actions. For instance, adequate levels of thyroid hormone are critical for the development of different tissues such as the central nervous system, but are also essential for the regulation of metabolic processes throughout life. The biological activity of thyroid hormone depends not only on serum thyroid hormone levels, but is also regulated at the tissue level by the expression and activity of deiodinases, which activate thyroid hormone or mediate its degradation. In addition, thyroid hormone transporters are necessary for the uptake of thyroid hormone into target tissues. With the discovery of monocarboxylate transporter 8 (MCT8) as a specific thyroid hormone transporter and the finding that mutations in this transporter lead to a syndrome of severe psychomotor retardation and elevated serum 3,3′,5-tri-iodothyronine levels known as the Allan–Herndon–Dudley syndrome, the interest in this area of research has greatly increased. In this review, we will focus on the molecular aspects of thyroid hormone transporters, including MCT8, MCT10, organic anion transporting polypeptides, and the effects of genetic variation in these transporters.
Introduction
Thyroid hormone is a pleiotropic hormone with widespread biological actions. The follicular cells of the thyroid gland produce predominantly thyroxine (T4), but it is mainly 3,3′,5-tri-iodothyronine (T3) that binds to the nuclear thyroid hormone receptor (Yen 2001). The biological activity of T3 is therefore largely determined by the intracellular T3 concentration which is dependent on a) the circulating T3 concentration; b) the transport of thyroid hormone across the cell membrane; and c) the presence of iodothyronine deiodinases, which activate or inactivate thyroid hormone. To date, three deiodinases have been characterized as homologous selenoproteins (Bianco et al. 2002). Both D1 and D2 converts T4 to T3, whereas D3 catalyzes the degradation of T4 to reverse T3 (rT3) and of T3 to 3,3′-T2.
The deiodinases are membrane proteins with their active sites located in the cytoplasm (Bianco et al. 2002). Therefore, transport across the cell membrane is essential for thyroid hormone action and metabolism. Based on the lipophilic structure of thyroid hormones, it is long thought that thyroid hormone enters the cell through passive diffusion. However, it has become increasingly clear that there are specific thyroid hormone transporters, and that the activity of these transporters in part determines the intracellular thyroid hormone concentration (Jansen et al. 2005).
To date, several transporters with high affinity for thyroid hormone, but with different tissue distributions and ligand affinities have been identified. This review will focus on the molecular aspects of the monocarboxylate transporter 8 (MCT8) and MCT10, and several members of the organic anion transporting polypeptide (OATP) family. Other transporters, such as the Na+-taurocholate co-transporting polypeptide, the L-type amino acid transporters (LAT1 and LAT2), and fatty acid translocase (CD36) will not be discussed as little is known about the effects of genetic variation in these transporters on cellular thyroid hormone transport. A review including these transporters has been published recently (van der Deure et al. 2007).
Besides molecular aspects, this review will focus on the effect of genetic variation in these transporters on cellular thyroid hormone transport. Polymorphisms are variations in the nucleotide sequence of the human genome that occurs in at least 1% of the general population. These polymorphisms determine differences between individuals, such as eye or hair color, but they also play a role in the variation of serum thyroid hormone levels that exists between individuals. Moreover, recent papers have indicated that polymorphism studies provide new insights into the role and activity of different proteins involved in thyroid hormone synthesis, metabolism, and transport (Peeters et al. 2006).
MCT8 and MCT10
Monocarboxylates, such as lactate, pyruvate, and ketone bodies, play an important role in energy metabolism in different tissues, in particular brain (Nehlig & Pereira de Vasconcelos 1993). The transport of these substances across the cell membrane is carried out by the proton-linked MCT1–4 (Halestrap & Meredith 2004). They belong to a larger family, consisting of 14 homologous proteins, but the function of most other members remains to be elucidated (Friesema et al. 2003, 2008). However, MCT10 has been characterized by Kim et al. (2002) as a T-type amino acid transporter, facilitating the cellular uptake and efflux of aromatic amino acids. Although this was not immediately clear, we have later shown that MCT10 is an active iodothyronine transporter (Friesema et al. 2008). This is reminiscent of the work of the group of Zhou et al. (1990, 1992), showing that thyroid hormone uptake into erythrocytes and other cell types is mediated by a T-type amino acid transporter.
The human MCT10 gene is located on chromosome 6q21–q22 and consists of six exons and five introns, of which the first intron is particularly large, i.e. ∼100 kb. This gene structure is identical to that of the human MCT8 gene, which was already identified in 1994 by Lafrenière et al. who showed that it is located on chromosome Xq13.2. On the basis of the presence of 12 putative transmembrane domains (TMDs), they hypothesized that the predicted protein represents a transporter (Lafreniere et al. 1994). The MCT8 and MCT10 proteins are highly homologous (Fig. 1), with an amino acid identity of 49% (Friesema et al. 2008). This homology is highest in the TMDs and lowest in the N- and C-terminal domains that are both located intracellularly.
Comparison of the protein structures of human MCT8 and MCT10. The yellow part of the MCT8 structure denotes the N-terminal domain that is present in the long MCT8 protein generated by use of the upstream translation start site. Indicated in green are the identical amino acid residues that occupy corresponding positions in MCT8 and MCT10. The blue lines represent the plasma membrane. The top of the figure is extracellular and the bottom is intracellular.
Citation: Journal of Molecular Endocrinology 44, 1; 10.1677/JME-09-0042
In humans, MCT8 may be expressed as a long 613-amino acid protein or a short 539-amino acid protein, depending on which of the two translation start sites (TLSs) is used. The MCT8 gene in most of the other species including rats and mice, only have the downstream TLS coding for the short MCT8 protein. The possible function of the N-terminal extension in the long human MCT8 protein as well as the possible differential regulation of the expression of the long versus short MCT8 proteins remains to be elucidated. In all species, MCT10 has only one TLS, giving rise to the production of the ‘short’ protein.
Friesema et al. (2003) demonstrated that rat and human MCT8 are active and specific iodothyronine transporters. Despite its high homology with MCT10 and MCT8 it does not transport (aromatic) amino acids. MCT8 also does not transport sulfonated iodothyronines or monocarboxylates such as lactate. The mechanisms by which MCT8 and MCT10 facilitate thyroid hormone uptake are unknown, but it has been demonstrated that iodothyronine transport is Na-independent. In view of the proton coupling of monocarboxylate transport by MCT1–4, the possible pH dependence of iodothyronine uptake by MCT8 and MCT10 needs to be investigated.
In transfected cells, both MCT8 and MCT10 increase the intracellular availability of iodothyronines, as evidenced by the marked increase in their intracellular deiodination by co-transfected deiodinases. However, both MCT8 and MCT10 facilitate not only the cellular uptake but also the efflux of iodothyronines. Since MCT10 appears more important for the export than for the import of aromatic amino acids (Ramadan et al. 2006, 2007), it is quite possible that cellular uptake of thyroid hormone is driven by the cellular efflux of aromatic amino acids through the same transporter. The trans-stimulation of T3 and T4 uptake by intracellular Trp has indeed been described in the studies of Francon and Blondeau (Zhou et al. 1990, 1992).
MCT8 is expressed in many tissues, including liver, kidney, heart, skeletal muscle, brain, and, strangely enough, thyroid. Mutations in the MCT8 gene cause a syndrome of severe psychomotor retardation and high serum T3 levels in affected male patients, known as the Allan–Herndon–Dudley syndrome. The neurological deficits are probably explained by an impeded uptake of T3 in MCT8-expressing central neurons and, hence, an impaired brain development. This has been reviewed in detail elsewhere (Dumitrescu et al. 2004, Friesema et al. 2004). Since mutations in the MCT8 gene have such profound effects, the question arises whether small changes in the MCT8 gene may affect transport activity as well.
Only two studies exist on the relationship between MCT8 polymorphic variants and serum thyroid hormone levels (van der Deure et al. 2007, Lago-Leston et al. 2008; Table 1). Lago-Leston et al. (2008) studied the serine-to-proline change at position 107 (Ser107Pro; rs6647476), which is the only established nonsynonymous polymorphism in MCT8. In their study, 276 healthy Spanish men were genotyped for this polymorphism. They found no association with serum thyroid hormone levels or with mRNA levels coding for MCT8 or thyroid hormone-responsive genes in white blood cells or in T3-stimulated fibroblasts.
Effect of common variation in monocarboxylate transporter-8 (MCT8) and MCT10
| rs Number polymorphism | Location | Change | Effect on serum thyroid hormone levels | In vitro effect | References | |
|---|---|---|---|---|---|---|
| Gene | ||||||
| MCT8 | rs6647476 | Exon | Ser107Pro | No effect observed | No effect observed | van der Deure et al. (2007) and Lago-Leston et al. (2008) |
| rs5937843 | Intron | G>T | Not consistent | Not determined | van der Deure et al. (2007) | |
| MCT10 | rs14399 | 3′-UTR | C>A | No effect observed | Not determined | van der Deure et al. (2007) |
We also genotyped this polymorphism in a population of 156 healthy men and women, and found no association between this variant and serum thyroid parameters either. Hemizygous carriers of a different polymorphism, i.e. rs5937843, located in intron 5 of the MCT8 gene, had lower free T4 (FT4) levels compared with wild-type male subjects. However, we failed to replicate these findings in the homozygous female carriers in the same population (van der Deure et al. 2007).
To date, only one study has been published regarding the possible association of genetic variation in the MCT10 gene with serum thyroid parameters. We showed that a common polymorphism (rs14399) in the 3′-UTR region of the MCT10 gene is not associated with serum thyroid hormone levels (van der Deure et al. 2007). The only established nonsynonymous polymorphism identified in human MCT10 is a lysine to glutamine change at position 508 (Lys508Gln; rs17072442), with a minor allele frequency of ∼2%. Considering the type of amino acid change, it would be interesting to investigate the association of this polymorphism with serum thyroid parameters and other thyroid-related endpoints.
So far, patients with mutations in MCT10 have not been identified. Considering the wide tissue distribution of MCT10 expression and its swift T3 transport, it is quite likely that MCT10 mutations are associated with significant alterations in tissue and/or serum thyroid hormone concentration. As is the case with MCT8, mutations in MCT10 may well result in a significant impairment of tissue T3 uptake and, thus, in manifestations of thyroid hormone resistance. At present, it is unclear, however, if MCT10 is significantly expressed in the pituitary and/or hypothalamus. Therefore, it remains to be seen if mutations in MCT10 result in a defect in the negative feedback control of TSH secretion like that seen in patients with thyroid hormone resistance because of mutations in the TRβ receptor.
To predict the phenotype of patients with MCT10 mutations, it would be highly interesting to study MCT10 knockout mice, although it should be realized that MCT8 knockout mice do not show any neurological abnormality in sharp contrast with the clinical condition of patients with MCT8 mutations (Dumitrescu et al. 2006, Trajkovic et al. 2007, Heuer & Visser 2009). However, MCT8 knockout mice replicate the endocrinological changes found in patients with the Allan–Herndon–Dudley syndrome: a marked increase in serum T3 and a decrease in serum T4 and rT3 (Dumitrescu et al. 2006, Trajkovic et al. 2007). The lack of any overt neurological abnormality may be explained by differences in expression patterns and specificities of thyroid hormone transporters between humans and rodents.
In the mouse brain, MCT8 is expressed not only in neurons but also in capillaries and the choroid plexus (Heuer et al. 2005, Roberts et al. 2008). The importance of MCT8 in the blood–brain barrier and in the blood–cerebral spinal fluid (CSF) barrier is strongly suggested by the almost complete block in brain T3 uptake in MCT8 knockout mice (Trajkovic et al. 2007). The lack of a neurological phenotype in these animals is explained by a compensatory increase in local T4 to T3 conversion by D2 expressed in astrocytes and the expression of alternative T3 transporters in neurons in rodents. Brain T4 uptake is not affected in MCT8 knockout mice, which is explained by the expression of the T4 transporter OATP1C1 in brain capillaries. Recently, Roberts et al. (2008) have shown that OATP1C1 is strongly expressed in mouse and rat cerebral microvessels, but not in human microvessels. This high expression of OATP1C1 in microvessels in rodents compared with human brain may contribute to the relatively mild phenotype observed in MCT8-null mice, in contrast to humans lacking functional MCT8.
OATPs
The OATPs are a large family of transporters responsible for Na+-independent transmembrane transport of amphipathic organic compounds, including bile salts, bromosulfophthalein (BSP), steroid hormones, and numerous drugs (Konig et al. 2006). So far, ∼40 OATPs have been identified in humans, rats, and mice. All OATPs are large proteins of 652–848 amino acids in length with 12 TMDs. Most OATP proteins are expressed in multiple tissues, including liver, kidney, brain (blood–brain barrier, choroid plexus), lung, heart, placenta, testis, eye, and small intestine (Hagenbuch & Meier 2003). However, some members show a tissue-specific distribution; OATP1B1 and OATP1B3 are exclusively expressed in liver (Hsiang et al. 1999, Konig et al. 2000), whereas OATP1C1 is only present in the brain and in the Leydig cells of the testis (Pizzagalli et al. 2002). Furthermore, most OATP family members are expressed at the basolateral membrane of polarized cells (Hsiang et al. 1999, Konig et al. 2000, Lee et al. 2005).
OATPs are generally involved in transport of both endo- and xenobiotics. Among the many ligands transported by OATPs, several members of this large family also facilitate uptake of thyroid hormone. These include members of the OATP1 subfamily: OATP1A2 (Fujiwara et al. 2001, Kullak-Ublick et al. 2001), OATP1B1 (Abe et al. 1999, Kullak-Ublick et al. 2001), OATP1B3 (Kullak-Ublick et al. 2001), and OATP1C1 (Pizzagalli et al. 2002); members of the OATP4 subfamily: OATP4A1 (Fujiwara et al. 2001) and OATP4C1 (Mikkaichi et al. 2004); and a member of the OATP6 subfamily: OATP6C1 (Suzuki et al. 2003). Interestingly, all human members of the OATP1 subfamily that transport thyroid hormone form a gene cluster together with a related pseudogene on chromosome 12p. In addition, they share on average almost 50% amino acid identity. The focus in this review will be on these four human members of the OATP1 subfamily, i.e. OATP1A2, OATP1B1, OATP1B3, and OATP1C1.
OATP1A2
OATP1A2, first cloned and characterized in 1995 as a transporter for bile salts and BSP in human liver by Kullak-Ublick et al. (1995), has been shown to transport T3 and T4 with Km values of 7 and 8 μM respectively (Fujiwara et al. 2001). In addition, we recently demonstrated that OATP1A2 facilitates not only transport of T4, T3, and rT3 but also of their sulfates T4S, T3S, and rT3S in transfected cells (unpublished data). OATP1A2 is expressed in multiple tissues, among which are liver, brain, and kidney (Kullak-Ublick et al. 1995, Gao et al. 2000). Based on its expression pattern, OATP1A2 could play a role in the delivery of thyroid hormone across the blood–brain barrier.
The high apparent Km values of OATP1A2-mediated T4 and T3 transport may not preclude a physiological role of OATP1A2 as a thyroid hormone transporter; they are in the same range as those determined for T4 and T3 transport by the physiologically important transporter MCT8. However, the low specificity of OATP1A2 suggests that thyroid hormone bioavailability for instance in the brain is not importantly regulated by this transporter. It may serve as a back-up transport system in case other transporters malfunction or are saturated, or when thyroid hormone concentrations are higher than normal. Alternatively, OATP1A2 could play a role in the clearance of thyroid hormone and its metabolites, for instance through elimination via bile or urine. Since iodothyronine sulfates, such as T4S, T3S, and rT3S, are regarded as waste products of thyroid hormone metabolism (Wu et al. 1993), this hypothesis seems to be plausible.
Like many OATPs, OATP1A2 plays a role in drug transport (Konig et al. 2006). Therefore, several papers have been published on the effect of OATP1A2 polymorphisms on drug pharmacokinetics. Badagnani et al. (2006) showed that genetic variation in the OATP1A2 gene might contribute to variation in methotrexate disposition and response. Two common (Ile13Thr and Glu172Asp) and two rare (Arg168Cys and Asn278X) protein-altering variants of OATP1A2 showed altered transport function. In a different study, Glu172Asp and Asn135Ile variants showed markedly reduced transport of the OATP1A2 substrates estrone sulfate (E1S) and deltorphin II (Lee et al. 2005). Other variants (Ala187Thr and Thr668Ser) appeared to have substrate-dependent changes in transport activity (Lee et al. 2005).
Since OATP1A2 transports thyroid hormone, we tested whether polymorphisms in the OATP1A2 gene have an effect on thyroid hormone transport in vitro. In addition, the variants were analyzed for association with serum thyroid parameters in two populations, i.e. a population of Caucasian blood donors (Peeters et al. 2003) and a large population of elderly Caucasian men and women of the Rotterdam Scan Study (Breteler 2000). We only studied the Ile13Thr and Glu172Asp polymorphisms, as other polymorphisms have an allele frequency <1% in Caucasians (Lee et al. 2005, Badagnani et al. 2006). The OATP1A2-Ile13Thr polymorphism was associated with higher T3 levels (Table 2). The OATP1A2-Glu172Asp was not consistently associated with serum thyroid hormone levels (Table 2).
Serum thyroid hormone levels by OATP1A2 genotypes in a population of Caucasian blood donors and in Caucasian men and women of the Rotterdam Scan Study
| Blood donors | Rotterdam Scan Study | |||||
|---|---|---|---|---|---|---|
| OATP1A2-Ile13Thr | OATP1A2-Ile13Thr | |||||
| Wild-type (116) | Carriers (33+1) | P | ||||
| TSHa | 1.31±0.07b | 1.40±0.13 | 0.26 | ND | ND | |
| FT4 | 15.2±0.2 | 14.5±0.4 | 0.14 | ND | ND | |
| T3 | 1.94±0.02 | 2.06±0.04 | 0.007 | ND | ND | |
| rT3 | 0.32±0.01 | 0.30±0.01 | 0.15 | ND | ND | |
| T4Sa | 17.53±0.55c | 17.55±1.03 | 0.82 | ND | ND | |
| OATP1A2-Glu172Asp | OATP1A2-Glu172Asp | |||||
|---|---|---|---|---|---|---|
| Wild-type (136) | Carriers (14) | P | Wild-type (839) | Carriers (100+6) | P | |
| TSHa | 1.34±0.07d | 1.24±0.20 | 0.90 | 1.41±0.04 | 1.35±0.10 | 0.16 |
| FT4 | 15.1±0.2 | 15.0±0.7 | 0.84 | 17.7±0.1 | 17.7±0.3 | 0.96 |
| T3 | 1.97±0.02 | 1.91±0.06 | 0.39 | 2.01±0.01 | 1.99±0.02 | 0.52 |
| rT3 | 0.31±0.01 | 0.36±0.02 | 0.02 | 0.34±0.01 | 0.35±0.01 | 0.21 |
| T4Sa | 17.50±0.51e | 17.22±1.61 | 0.95 | ND | ND | |
Data are corrected for age and gender and shown as mean±s.e.m. ND, not determined.
Due to a nonnormal distribution, TSH and T4S were logarithmically transformed in the analysis.
N=115.
N=117.
N=135.
N=137.
Except for transport of T4S, no differences in thyroid hormone transport were observed between OATP1A2-Ile13Thr and wild-type OATP1A2 in vitro. However, cells transfected with the OATP1A2-Glu172Asp variant showed decreased transport compared with cells transfected with wild-type OATP1A2 (Fig. 2). Metabolism of (sulfated) iodothyronines co-transfected deiodinases was decreased in a similar manner in cells transfected with OATP1A2-Glu172Asp compared with cells transfected with wild-type OATP1A2 (data not shown). Our in vitro data are in line with previous data from Badagnani et al. (2006). Lee et al. (2005) however, also showed decreased transport by the OATP1A2-Ile13Thr variant. The discrepancy between their and our findings might be explained by substrate-dependent changes in transport activity.
[125I]T3, [125I]T4, [125I]T3S, and [125I]T4S uptake by COS1 cells transfected with empty vector, wild-type OATP1A2, OATP1A2-Ile13Thr, or OATP1A2-Glu172Asp. Cells were co-transfected with μ-crystallin (Vie et al. 1997). Cells were incubated for 30 min at 37 °C with 1 nM [125I]T3, T4, T3S, or T4S. Data are expressed as percentage uptake of added radioactivity. Results are the means±s.e.m. of three experiments. *P<0.05 for OATP1A2-Ile13Thr or OATP1A2-Glu172Asp versus wild-type OATP1A2.
Citation: Journal of Molecular Endocrinology 44, 1; 10.1677/JME-09-0042
Although the OATP1A2-Glu172Asp showed decreased transport activity in vitro, this variant was not associated with serum thyroid parameters in two populations of Caucasians. Therefore, OATP1A2 may not play an important role in thyroid hormone transport in a physiological situation. Alternatively, the polymorphism may affect tissue thyroid hormone concentrations independent of serum levels.
OATP1B1 and OATP1B3
OATP1B1 and OATP1B3 are exclusively expressed in liver and share ∼80% amino acid identity with each other (Abe et al. 1999, 2001). Both transporters have broad substrate specificities as they transport numerous compounds such as bilirubin, bile salts, drugs such as pravastatin and digoxin, but also steroid hormone conjugates (Hagenbuch & Meier 2003). Many studies have been published on the role of these two proteins in drug absorption, distribution, and excretion (Konig et al. 2006, Niemi 2007). They are involved in the cellular uptake of drugs into the liver which, besides the intestine and the kidneys, is an important tissue determining the pharmacokinetics of drugs.
Recent studies have shown that OATP1B1 markedly stimulates uptake of the iodothyronine sulfates T4S, T3S, and rT3S but has little activity towards nonsulfated T4, T3, and rT3 (van der Deure et al. 2008b). Like OATP1B1, OATP1B3 preferentially transports the sulfated iodothyronines as well as rT3 (unpublished data, WM van der Deure, ECH Friesema, RP Peeters & TJ Vissers). Under normal conditions, D1 in liver rapidly degradates rT3 and sulfated iodothyronines, keeping the serum concentrations of these metabolites low (Chopra et al. 1992, 1993, Wu et al. 1992, 1993, 2005, Bianco et al. 2002). However, serum iodothyronine sulfates and rT3 levels are high in preterm infants and during critical illness, possibly due to decreased degradation (Chopra et al. 1992, 1993, Peeters et al. 2005). It is therefore of interest that both OATP1B1 and OATP1B3 only facilitate transport of the iodothyronine sulfates and rT3. This suggests that OATP1B1 and OATP1B3 play an important role in hepatic transport and metabolism of iodothyronine sulfates, reflecting their role in the transport of endo- and xenobiotics that are metabolized in the liver and excreted in the bile.
Polymorphisms in the OATP1B1 and OATP1B3 genes have been extensively studied as they impact on the interindividual variability of drug disposition and drug response (Smith et al. 2005). To date, only one study has focused on associations between a polymorphism in the OATP1B1 gene, OATP1B1-Val174Ala, and serum thyroid hormone levels. Niemi et al. (2005) have previously shown that the OATP1B1-Val174Ala polymorphism leads to decreased function of OATP1B1 and thereby increases the systemic bioavailability of lipid-lowering drugs.
As we showed that OATP1B1 preferentially transports sulfated hormones, i.e. T4S, T3S, rT3S, and E1S (van der Deure et al. 2008b), we expected that the OATP1B1-Val174Ala polymorphism would be associated with serum levels of iodothyronine sulfates and E1S. Indeed, this polymorphism was associated with higher serum T4S levels in 155 blood donors, while in a larger cohort of elderly Caucasians this same polymorphism was associated with 40% higher serum E1S levels. Unfortunately, we were not able to replicate these findings as no serum was left to determine E1S and T4S levels in the healthy blood donors and elderly Caucasians respectively. However, in vitro OATP1B1-Ala174 showed a 40% lower induction of transport and metabolism of these substrates than OATP1B1-Val174 in transfected COS1 cells (van der Deure et al. 2008b; Fig. 3). Decreased hepatic uptake of T4S and E1S by OATP1B1-Ala174 compared with OATP-Val174 in vivo thus gives rise to higher serum T4S and E1S levels.
[125I]T4S and [3H]E1S uptake by COS1 cells transfected with empty vector, OATP1B1-Val174, or OATP1B1-Ala174. Cells were incubated at 37 °C with 1 nM [125I]T4S or 100 nM [3H]E1S for different time periods. Data are expressed as percentage uptake of added radioactivity. Results are the means±s.e.m. of three experiments. (a) P<0.05 for OATP1B1-Val174 versus OATP1B1-Ala174 and versus empty vector and (b) P<0.05 for OATP1B1-Ala174 versus empty vector.
Citation: Journal of Molecular Endocrinology 44, 1; 10.1677/JME-09-0042
Concerning the association of the OATP1B1-Val174Ala polymorphism and E1S levels, it would be interesting to study OATP1B1 as a risk factor in the development of breast cancer. In contrast to the role of sulfation in thyroid hormone metabolism, the sulfation of estrogens is readily reversible by estrogen sulfatase (Reed et al. 2005). E1S is thought to serve as a reservoir for active estrogens, for instance in breast tissue, since serum concentrations of E1S are 10–20 times higher than those of the unconjugated estrogens (Ruder et al. 1972).
Estrogens play an important role in the initiation and growth of breast cancer. Therefore, therapies aim at blocking their interaction with the estrogen receptor by use of an anti-estrogen, or by inhibiting the conversion of androstenedione to estrone with an aromatase inhibitor (Cole et al. 1971, Smith & Dowsett 2003). Local formation of estrogens in breast tumors might be more important than circulating estrogens for growth and survival of estrogen-dependent breast cancer in postmenopausal women (Nakata et al. 2003). Serum E1S is a major source of estrogens for breast tissue through local sulfatase activity (Gamage et al. 2006). The role of OATP1B1 in the risk of developing breast cancer should therefore be investigated, since carriers of the OATP1B1-Val174Ala polymorphism have life-long higher serum E1S levels (van der Deure et al. 2008b).
To date, no studies have been published on associations between genetic variation in the OATP1B3 gene and serum thyroid hormone levels. A recent paper by Smith et al. demonstrated that genetic variation in OATP1B3 played a limited role in the disposition of the anti-cancer agent paclitaxel. They studied three nonsynonymous polymorphisms, i.e. Ser112Ala, Met233Ile, and Gly522Cys. We genotyped the Ser112Ala and Met233Ile polymorphisms in a population of 156 healthy men and women. These polymorphisms are in complete linkage disequilibrium with each other (www.ncbi.nlm.nih.gov) and show no association with serum thyroid parameters (Table 3).
Serum thyroid hormone levels by OATP1B3 genotypes in a population of Caucasian blood donors
| Blood donors | |||
|---|---|---|---|
| Wild-type (102) | Carriers (45+6) | P | |
| OATP1B3-Ser112Ala | |||
| TSHa | 1.28±0.08 | 1.38±0.11b | 0.13 |
| FT4 | 14.9±0.2 | 15.5±0.3 | 0.13 |
| T3 | 1.97±0.02 | 1.96±0.03 | 0.80 |
| rT3 | 0.31±0.01 | 0.32±0.01 | 0.20 |
| T4Sa | 17.61±0.59c | 17.54±0.84 | 0.82 |
| OATP1B3-Met233Ile | |||
| TSHa | 1.28±0.08 | 1.38±0.11b | 0.13 |
| FT4 | 14.9±0.2 | 15.5±0.3 | 0.13 |
| T3 | 1.97±0.02 | 1.96±0.03 | 0.80 |
| rT3 | 0.31±0.01 | 0.32±0.01 | 0.20 |
| T4Sa | 17.61±0.59c | 17.54±0.84 | 0.82 |
Data are corrected for age and gender and shown as mean±s.e.m.
Owing to a non-normal distribution, TSH and T4S were logarithmically transformed in the analysis.
N=50.
N=103.
OATP1C1
Virtually all OATPs transport numerous substrates. A notable exception to this multi-specific transport capacitiy is OATP1C1. Pizzagalli et al. (2002) demonstrated that it shows a high preference for T4 and rT3. We recently extended these findings by showing that T4S uptake is also facilitated by OATP1C1 although less effectively than T4 (van der Deure et al. 2008c). Together, with the almost exclusive expression at the blood–brain barrier, this suggests that OATP1C1 is critical for T4 uptake into the brain. This important role is substantiated by Sugiyama et al. (2003) who showed that expression levels of OATP1C1 in isolated rat brain capillaries are regulated by thyroid hormone concentrations. Oatp1c1 is up-regulated in hypothyroid rats and down-regulated in hyperthyroid rats (Sugiyama et al. 2003). Together with changes in D2 expression (Forrest et al. 2002), OATP1C1 counteracts the effect of alterations in serum T4 to ensure stable thyroid hormone concentrations in the brain.
Recently, OATP1C1 homologs have been identified in chicken and mice (Tohyama et al. 2004, Nakao et al. 2006). Similar to its human ortholog, mouse Oatp1c1 transports T4 and rT3 with high affinity and is widely expressed in brain, suggesting an important role in T4 transport across the blood–brain barrier (Tohyama et al. 2004). Nakao et al. demonstrated that also in chicken Oatp1c1 transports T4.
Whether findings regarding the role of OATP1C1 in mice, rats, and chicken can be extrapolated to humans, remains to be investigated. For instance, in a recent report Roberts et al. (2008) showed the expression of OATP1C1 is higher in rodents compared with human brain. However, due to the high level of homology in structure and substrate specificity between rodent and human OATP1C1, it seems plausible that OATP1C1 is also important for T4 uptake in the human brain. This is supported by our data showing that polymorphisms in the OATP1C1 gene are associated with fatigue and depression in a cohort of hypothyroid patients (van der Deure et al. 2008a). Considering the presumed function of T4 transport across the blood–brain barrier, mutations in OATP1C1 are expected to have a significant impact on brain development and function. Loss of OATP1C1 function may well lead to neuronal deficits similar to those seen in subjects with untreated congenital hypothyroidism or in patients with MCT8 mutations (Sugiyama et al. 2003). It seems worthwhile to study this in OATP1C1 knockout mice.
OATP1C1 is capable of T4, T4S, and rT3 transport, but polymorphisms in the OATP1C1 gene are not consistently associated with serum thyroid hormone levels (van der Deure et al. 2008c). Although, the OATP1C1-Pro143Thr and OATP1C1-C3035T polymorphisms were associated with serum thyroid parameters in 156 blood donors, we could not replicate these findings in a much larger cohort of Danish twins. Nor did we observe any differences in uptake and metabolism of T4 and rT3 between these variants and wild-type OATP1C1. In addition, no associations were found between the OATP1C1-intron3C>T polymorphism and serum thyroid hormone levels (van der Deure et al. 2008c).
However, both OATP1C1-intron3C>T and OATP1C1-C3035T polymorphisms, but not the OATP1C1-Pro143Thr polymorphism, were associated with symptoms of fatigue and depression in a population of adequately treated hypothyroid patients (van der Deure et al. 2008a). This is of interest as recently a number of papers have reported on effects of polymorphisms in thyroid hormone pathway genes, independent of an effect on serum thyroid hormone levels (Mentuccia et al. 2002, Canani et al. 2005). In a recent review, Panicker has shown that most of the associations between polymorphisms in thyroid hormone pathway genes and thyroid hormone-related endpoints were independent of serum thyroid hormone levels, which highlight the importance of local regulation of thyroid hormones in tissues (Dayan & Panicker 2009). In addition, it demonstrates that polymorphism studies can provide new insights into the role of thyroid hormone in the human body. It should be stressed, however, that functional consequences of polymorphisms in OATP1C1 have not been demonstrated in vitro.
Table 4 presents a summary of the studies discussed above regarding the possible effects of polymorphisms in the different OATP1 transporters on serum thyroid hormone levels in vivo and on the rate of iodothyronine transport in vitro.
Effect of common variation in OATP1A2, OATP1B1, OATP1B3 and OATP1C1
| Polymorphism | Location | Change | Effect on serum thyroid hormone levels | In vitro effect | References | |
|---|---|---|---|---|---|---|
| Gene | ||||||
| OATP1A2 | rs57921276 | Exon | Ile13Thr | No effect observed | No effect observed | Table 2 and Fig. 2 |
| rs57550534 | Exon | Glu172Asp | No effect observed | Decreased transport capacity | ||
| OATP1B1 | rs4149056 | Val174Ala | Higher bilirubin, T4S, E1S levels, lower T3/rT3 ratio | Decreased transport capacity | van der Deure et al. (2008b) | |
| OATP1B3 | rs4149117 | Exon | Ser112Ala | No effect observed | Not determined | Table 3 |
| rs7311358 | Exon | Met233Ile | No effect observed | Not determined | ||
| OATP1C1 | rs10770704 | Intron | C/T | No effect observed | Not determined | van der Deure et al. (2008c) |
| rs36010656 | Exon | Pro143Thr | Higher rT3 levels, however, effect not consistent | No effect observed | ||
| rs10444412 | 3′-UTR | C3035T | Higher FT4 and rT3 levels, however, effect not consistent | No effect observed |
Concluding remarks and future studies
Until only a few years ago, transport of thyroid hormone was thought to be a passive diffusion process. However, it has become clear that thyroid hormone requires active transport across cell membrane to carry out its biological functions. The importance of transport for thyroid hormone action was highlighted by the discovery of MCT8 as an active thyroid hormone transporter and by the notion that mutations in the MCT8 gene lead to the Allan–Herndon–Dudley syndrome. In this review, we have discussed the molecular aspects of MCT8, MCT10 and the human members of the OATP1 family. In addition, we have discussed several studies dealing with polymorphisms in different thyroid hormone transporters.
It is surprising that few studies have been published investigating the association of polymorphisms in these transporters with serum thyroid parameters or thyroid hormone-related endpoints, especially since polymorphism studies have yielded new insights into the role of thyroid hormone in several processes in the human body. For instance, a genome-wide linkage scan identified the type 2 deiodinase as a susceptibility locus for osteoarthritis (Meulenbelt et al. 2008). In addition, genetic variation seems to play a role in psychological well-being (van der Deure et al. 2008a). However, there is also conflicting data about the role of D2 in diabetes (Mentuccia et al. 2002, Maia et al. 2007, Peeters et al. 2007). In addition, some associations are preliminary and need to be replicated in larger cohorts. Nevertheless, these studies provide a powerful tool to study thyroid hormone action in humans.
Many genes are involved in thyroid hormone action and metabolism. So far, studies have been published focusing on polymorphisms in the TSH receptor, in the deiodinases (for a recent review see Peeters et al. (2006)) and to a lesser extent also in thyroid hormone transporters and thyroid hormone receptors using a candidate gene approach. Owing to disappointing results of studies that employ a candidate gene approach, more and more studies use a genome-wide association (GWA) strategy, which is made possible through rapid technical progress over the recent years. In such a GWA study, the genome of each individual in the population is genotyped for more than 500 000 polymorphisms to search for variants that are associated with the phenotype of interest.
Although a GWA study is complicated, as it requires large samples sizes, replication and reliable geno- and phenotyping, it will unravel previously unknown pathways involved in thyroid hormone metabolism. Panicker et al. (2008) identified several loci associated with serum FT4 and TSH by a genome-wide linkage scan with 737 microsatellite markers, but as expected from an underpowered linkage scan in related subjects, they did not identify the actual genes explaining the variation in serum thyroid hormone levels. Arnaud-Lopez et al. (2008) have recently demonstrated that polymorphisms in the phosphodiesterase 8B gene are associated with serum TSH levels and thyroid function. It is, therefore, likely that more new insights will be obtained in the near future.
Declaration of interest
The authors have nothing to disclose.
Funding
This work was supported by the Netherlands Organization of Scientific Research (NOW; RIDE grant 014-93-015).
References
Abe T, Kakyo M, Tokui T, Nakagomi R, Nishio T, Nakai D, Nomura H, Unno M, Suzuki M & Naitoh T et al. 1999 Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. Journal of Biological Chemistry 274 17159–17163.
Abe T, Unno M, Onogawa T, Tokui T, Kondo TN, Nakagomi R, Adachi H, Fujiwara K, Okabe M & Suzuki T et al. 2001 LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology 120 1689–1699.
Arnaud-Lopez L, Usala G, Ceresini G, Mitchell BD, Pilia MG, Piras MG, Sestu N, Maschio A, Busonero F & Albai G et al. 2008 Phosphodiesterase 8B gene variants are associated with serum TSH levels and thyroid function. American Journal of Human Genetics 82 1270–1280.
Badagnani I, Castro RA, Taylor TR, Brett CM, Huang CC, Stryke D, Kawamoto M, Johns SJ, Ferrin TE & Carlson EJ et al. 2006 Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. Journal of Pharmacology and Experimental Therapeutics 318 521–529.
Bianco AC, Salvatore D, Gereben B, Berry MJ & Larsen PR 2002 Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocrine Reviews 23 38–89.
Breteler MM 2000 Vascular involvement in cognitive decline and dementia. Epidemiologic evidence from the Rotterdam Study and the Rotterdam Scan Study. Annals of the New York Academy of Sciences 903 457–465.
Canani LH, Capp C, Dora JM, Meyer EL, Wagner MS, Harney JW, Larsen PR, Gross JL, Bianco AC & Maia AL 2005 The type 2 deiodinase A/G (Thr92Ala) polymorphism is associated with decreased enzyme velocity and increased insulin resistance in patients with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism 90 3472–3478.
Chopra IJ, Wu SY, Teco GN & Santini F 1992 A radioimmunoassay for measurement of 3,5,3′-triiodothyronine sulfate: studies in thyroidal and nonthyroidal diseases, pregnancy, and neonatal life. Journal of Clinical Endocrinology and Metabolism 75 189–194.
Chopra IJ, Santini F, Hurd RE & Chua Teco GN 1993 A radioimmunoassay for measurement of thyroxine sulfate. Journal of Clinical Endocrinology and Metabolism 76 145–150.
Cole MP, Jones CT & Todd ID 1971 A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. British Journal of Cancer 25 270–275.
Dayan CM & Panicker V 2009 Novel insights into thyroid hormones from the study of common genetic variation. Nature Reviews. Endocrinology 5 211–218.
van der Deure WM, Peeters RP & Visser TJ 2007 Genetic variation in thyroid hormone transporters. Best Practice and; Research. Clinical Endocrinology and Metabolism 21 339–350.
van der Deure WM, Appelhof BC, Peeters RP, Wiersinga WM, Wekking EM, Huyser J, Schene AH, Tijssen JG, Hoogendijk WJ & Visser TJ et al. 2008a Polymorphisms in the brain-specific thyroid hormone transporter OATP1C1 are associated with fatigue and depression in hypothyroid patients. Clinical Endocrinology 69 804–811.
van der Deure WM, Friesema EC, de Jong FJ, de Rijke YB, de Jong FH, Uitterlinden AG, Breteler MM, Peeters RP & Visser TJ 2008b Organic anion transporter 1B1: an important factor in hepatic thyroid hormone and estrogen transport and metabolism. Endocrinology 149 4695–4701.
van der Deure WM, Hansen PS, Peeters RP, Kyvik KO, Friesema EC, Hegedus L & Visser TJ 2008c Thyroid hormone transport and metabolism by organic anion transporter 1C1 and consequences of genetic variation. Endocrinology 149 5307–5314.
Dumitrescu AM, Liao XH, Best TB, Brockmann K & Refetoff S 2004 A novel syndrome combining thyroid and neurological abnormalities is associated with mutations in a monocarboxylate transporter gene. American Journal of Human Genetics 74 168–175.
Dumitrescu AM, Liao XH, Weiss RE, Millen K & Refetoff S 2006 Tissue-specific thyroid hormone deprivation and excess in monocarboxylate transporter (MCT) 8-deficient mice. Endocrinology 147 4036–4043.
Forrest D, Reh TA & Rusch A 2002 Neurodevelopmental control by thyroid hormone receptors. Current Opinion in Neurobiology 12 49–56.
Friesema EC, Ganguly S, Abdalla A, Manning Fox JE, Halestrap AP & Visser TJ 2003 Identification of monocarboxylate transporter 8 as a specific thyroid hormone transporter. Journal of Biological Chemistry 278 40128–40135.
Friesema EC, Grueters A, Biebermann H, Krude H, von Moers A, Reeser M, Barrett TG, Mancilla EE, Svensson J & Kester MH et al. 2004 Association between mutations in a thyroid hormone transporter and severe X-linked psychomotor retardation. Lancet 364 1435–1437.
Friesema EC, Jansen J, Jachtenberg JW, Visser WE, Kester MH & Visser TJ 2008 Effective cellular uptake and efflux of thyroid hormone by human monocarboxylate transporter 10. Molecular Endocrinology 22 1357–1369.
Fujiwara K, Adachi H, Nishio T, Unno M, Tokui T, Okabe M, Onogawa T, Suzuki T, Asano N & Tanemoto M et al. 2001 Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner. Endocrinology 142 2005–2012.
Gamage N, Barnett A, Hempel N, Duggleby RG, Windmill KF, Martin JL & McManus ME 2006 Human sulfotransferases and their role in chemical metabolism. Toxicological Sciences 90 5–22.
Gao B, Hagenbuch B, Kullak-Ublick GA, Benke D, Aguzzi A & Meier PJ 2000 Organic anion-transporting polypeptides mediate transport of opioid peptides across blood–brain barrier. Journal of Pharmacology and Experimental Therapeutics 294 73–79.
Hagenbuch B & Meier PJ 2003 The superfamily of organic anion transporting polypeptides. Biochimica et Biophysica Acta 1609 1–18.
Halestrap AP & Meredith D 2004 The SLC16 gene family-from monocarboxylate transporters (MCTs) to aromatic amino acid transporters and beyond. Pflugers Archiv 447 619–628.
Heuer H & Visser TJ 2009 Minireview: pathophysiological importance of thyroid hormone transporters. Endocrinology 150 1078–1083.
Heuer H, Maier MK, Iden S, Mittag J, Friesema EC, Visser TJ & Bauer K 2005 The monocarboxylate transporter 8 linked to human psychomotor retardation is highly expressed in thyroid hormone-sensitive neuron populations. Endocrinology 146 1701–1706.
Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP & Kirchgessner TG 1999 A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. Journal of Biological Chemistry 274 37161–37168.
Jansen J, Friesema EC, Milici C & Visser TJ 2005 Thyroid hormone transporters in health and disease. Thyroid 15 757–768.
Kim DK, Kanai Y, Matsuo H, Kim JY, Chairoungdua A, Kobayashi Y, Enomoto A, Cha SH, Goya T & Endou H 2002 The human T-type amino acid transporter-1: characterization, gene organization, and chromosomal location. Genomics 79 95–103.
Konig J, Cui Y, Nies AT & Keppler D 2000 A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. American Journal of Physiology. Gastrointestinal and Liver Physiology 278 G156–G164.
Konig J, Seithel A, Gradhand U & Fromm MF 2006 Pharmacogenomics of human OATP transporters. Naunyn-Schmiedeberg's Archives of Pharmacology 372 432–443.
Kullak-Ublick GA, Hagenbuch B, Stieger B, Schteingart CD, Hofmann AF, Wolkoff AW & Meier PJ 1995 Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology 109 1274–1282.
Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ & Hagenbuch B 2001 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 120 525–533.
Lafreniere RG, Carrel L & Willard HF 1994 A novel transmembrane transporter encoded by the XPCT gene in Xq13.2. Human Molecular Genetics 3 1133–1139.
Lago-Leston R, Iglesias MJ, San-Jose E, Areal C, Eiras A, Araujo-Vilar D, Lado-Abeal J & Dominguez-Gerpe L 2008 Prevalence and functional analysis of the S107P polymorphism (rs6647476) of the monocarboxylate transporter 8 (SLC16A2) gene in the male population of Northwest Spain (Galicia). Clinical Endocrinology.
Lee W, Glaeser H, Smith LH, Roberts RL, Moeckel GW, Gervasini G, Leake BF & Kim RB 2005 Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry. Journal of Biological Chemistry 280 9610–9617.
Maia AL, Dupuis J, Manning A, Liu C, Meigs JB, Cupples LA, Larsen PR & Fox CS 2007 The type 2 deiodinase (DIO2) A/G polymorphism is not associated with glycemic traits: the Framingham Heart Study. Thyroid 17 199–202.
Mentuccia D, Proietti-Pannunzi L, Tanner K, Bacci V, Pollin TI, Poehlman ET, Shuldiner AR & Celi FS 2002 Association between a novel variant of the human type 2 deiodinase gene Thr92Ala and insulin resistance: evidence of interaction with the Trp64Arg variant of the beta-3-adrenergic receptor. Diabetes 51 880–883.
Meulenbelt I, Min JL, Bos S, Riyazi N, Houwing-Duistermaat JJ, van der Wijk HJ, Kroon HM, Nakajima M, Ikegawa S & Uitterlinden AG et al. 2008 Identification of DIO2 as a new susceptibility locus for symptomatic osteoarthritis. Human Molecular Genetics 17 1867–1875.
Mikkaichi T, Suzuki T, Onogawa T, Tanemoto M, Mizutamari H, Okada M, Chaki T, Masuda S, Tokui T & Eto N et al. 2004 Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. PNAS 101 3569–3574.
Nakao N, Takagi T, Iigo M, Tsukamoto T, Yasuo S, Masuda T, Yanagisawa T, Ebihara S & Yoshimura T 2006 Possible involvement of organic anion transporting polypeptide 1c1 in the photoperiodic response of gonads in birds. Endocrinology 147 1067–1073.
Nakata T, Takashima S, Shiotsu Y, Murakata C, Ishida H, Akinaga S, Li PK, Sasano H, Suzuki T & Saeki T 2003 Role of steroid sulfatase in local formation of estrogen in post-menopausal breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology 86 455–460.
Nehlig A & Pereira de Vasconcelos A 1993 Glucose and ketone body utilization by the brain of neonatal rats. Progress in Neurobiology 40 163–221.
Niemi M 2007 Role of OATP transporters in the disposition of drugs. Pharmacogenomics 8 787–802.
Niemi M, Backman JT, Kajosaari LI, Leathart JB, Neuvonen M, Daly AK, Eichelbaum M, Kivisto KT & Neuvonen PJ 2005 Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clinical Pharmacology and Therapeutics 77 468–478.
Panicker V, Wilson SG, Spector TD, Brown SJ, Kato BS, Reed PW, Falchi M, Richards JB, Surdulescu GL & Lim EM et al. 2008 Genetic loci linked to pituitary–thyroid axis setpoints: a genome-wide scan of a large twin cohort. Journal of Clinical Endocrinology and Metabolism 93 3519–3523.
Peeters RP, van Toor H, Klootwijk W, de Rijke YB, Kuiper GG, Uitterlinden AG & Visser TJ 2003 Polymorphisms in thyroid hormone pathway genes are associated with plasma TSH and iodothyronine levels in healthy subjects. Journal of Clinical Endocrinology and Metabolism 88 2880–2888.
Peeters RP, Kester MH, Wouters PJ, Kaptein E, van Toor H, Visser TJ & Van den Berghe G 2005 Increased thyroxine sulfate levels in critically ill patients as a result of a decreased hepatic type I deiodinase activity. Journal of Clinical Endocrinology and Metabolism 90 6460–6465.
Peeters RP, van der Deure WM & Visser TJ 2006 Genetic variation in thyroid hormone pathway genes; polymorphisms in the TSH receptor and the iodothyronine deiodinases. European Journal of Endocrinology 155 655–662.
Peeters RP, van der Deure WM, van den Beld AW, van Toor H, Lamberts SW, Janssen JA, Uitterlinden AG & Visser TJ 2007 The Asp727Glu polymorphism in the TSH receptor is associated with insulin resistance in healthy elderly men. Clinical Endocrinology 66 808–815.
Pizzagalli F, Hagenbuch B, Stieger B, Klenk U, Folkers G & Meier PJ 2002 Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter. Molecular Endocrinology 16 2283–2296.
Ramadan T, Camargo SM, Summa V, Hunziker P, Chesnov S, Pos KM & Verrey F 2006 Basolateral aromatic amino acid transporter TAT1 (Slc16a10) functions as an efflux pathway. Journal of Cell Physiology 206 771–779.
Ramadan T, Camargo SM, Herzog B, Bordin M, Pos KM & Verrey F 2007 Recycling of aromatic amino acids via TAT1 allows efflux of neutral amino acids via LAT2-4F2hc exchanger. Pflugers Archiv 454 507–516.
Reed MJ, Purohit A, Woo LW, Newman SP & Potter BV 2005 Steroid sulfatase: molecular biology, regulation, and inhibition. Endocrine Reviews 26 171–202.
Roberts LM, Woodford K, Zhou M, Black DS, Haggerty JE, Tate EH, Grindstaff KK, Mengesha W, Raman C & Zerangue N 2008 Expression of the thyroid hormone transporters monocarboxylate transporter-8 (SLC16A2) and organic ion transporter-14 (SLCO1C1) at the blood–brain barrier. Endocrinology 149 6251–6261.
Ruder HJ, Loriaux L & Lipsett MB 1972 Estrone sulfate: production rate and metabolism in man. Journal of Clinical Investigation 51 1020–1033.
Smith IE & Dowsett M 2003 Aromatase inhibitors in breast cancer. New England Journal of Medicine 348 2431–2442.
Smith NF, Figg WD & Sparreboom A 2005 Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination. Expert Opinion on Drug Metabolism and Toxicology 1 429–445.
Sugiyama D, Kusuhara H, Taniguchi H, Ishikawa S, Nozaki Y, Aburatani H & Sugiyama Y 2003 Functional characterization of rat brain-specific organic anion transporter (Oatp14) at the blood–brain barrier: high affinity transporter for thyroxine. Journal of Biological Chemistry 278 43489–43495.
Suzuki T, Onogawa T, Asano N, Mizutamari H, Mikkaichi T, Tanemoto M, Abe M, Satoh F, Unno M & Nunoki K et al. 2003 Identification and characterization of novel rat and human gonad-specific organic anion transporters. Molecular Endocrinology 17 1203–1215.
Tohyama K, Kusuhara H & Sugiyama Y 2004 Involvement of multispecific organic anion transporter, Oatp14 (Slc21a14), in the transport of thyroxine across the blood–brain barrier. Endocrinology 145 4384–4391.
Trajkovic M, Visser TJ, Mittag J, Horn S, Lukas J, Darras VM, Raivich G, Bauer K & Heuer H 2007 Abnormal thyroid hormone metabolism in mice lacking the monocarboxylate transporter 8. Journal of Clinical Investigation 117 627–635.
Vie MP, Evrard C, Osty J, Breton-Gilet A, Blanchet P, Pomerance M, Rouget P, Francon J & Blondeau JP 1997 Purification, molecular cloning, and functional expression of the human nicodinamide-adenine dinucleotide phosphate-regulated thyroid hormone-binding protein. Molecular Endocrinology 11 1728–1736.
Wu SY, Huang WS, Polk D, Florsheim WH, Green WL & Fisher DA 1992 Identification of thyroxine-sulfate (T4S) in human serum and amniotic fluid by a novel T4S radioimmunoassay. Thyroid 2 101–105.
Wu SY, Huang WS, Polk D, Chen WL, Reviczky A, Williams J III, Chopra IJ & Fisher DA 1993 The development of a radioimmunoassay for reverse triiodothyronine sulfate in human serum and amniotic fluid. Journal of Clinical Endocrinology and Metabolism 76 1625–1630.
Wu SY, Green WL, Huang WS, Hays MT & Chopra IJ 2005 Alternate pathways of thyroid hormone metabolism. Thyroid 15 943–958.
Yen PM 2001 Physiological and molecular basis of thyroid hormone action. Physiological Reviews 81 1097–1142.
Zhou Y, Samson M, Osty J, Francon J.& & Blondeau JP 1990 Evidence for a close link between the thyroid hormone transport system and the aromatic amino acid transport system T in erythrocytes. Journal of Biological Chemistry 265 17000–17004.
Zhou Y, Samson M, Francon J & Blondeau JP 1992 Thyroid hormone concentrative uptake in rat erythrocytes. Involvement of the tryptophan transport system T in countertransport of tri-iodothyronine and aromatic amino acids. Biochemical Journal 281 81–86.
